RxSight, Inc. (RXST) stock forecast and price target
Price $5.32 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($5.32)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.13 | +29.6% | $147M |
| Next fiscal year ends December 31, 2027 | $-0.67 | −432.7% | $116M |
| Next quarter ends December 31, 2026 | $0.33 | +1215.4% | $58M |
| Quarter after ends March 31, 2027 | $-0.14 | +28.9% | $30M |
Consensus of the analysts covering RxSight, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Our model vs. Wall Street
Analysts see 14.7% upside over 12 months. Our discounted cash flow model with moderate assumptions puts RxSight’s intrinsic value about 79% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the RxSight stock price target?
The average 12-month target from 8 analysts is $6.10, 14.7% above the current price of $5.32 Targets range from $5.00 to $8.00.
Is RxSight a buy according to analysts?
The consensus rating is “Hold” (1 strong buy, 7 hold, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is RxSight expected to earn?
Analysts expect EPS of $-0.13 for the fiscal year ending December 31, 2026 and $-0.67 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.